Advair Diskus Generic Now Available for COPD and Asthma

Wixela Inhub (fluticasone propionate and salmeterol inhalation powder), the first substitutable generic of Advair Diskus (GlaxoSmithKline), has been made available by Mylan for the treatment of asthma in patients aged 4 years not adequately controlled on long-term asthma medications or whose disease warrants initiation of treatment with both inhaled corticosteroids and long-acting beta agonists; maintenance treatment of COPD; and the reduction of COPD exacerbations in patients with a history of exacerbations.

Mylan’s therapeutically equivalent generic will be offered at a wholesale acquisition cost that is 70% less than the brand product. Wixela Inhub is available in 3 strengths: 100mcg/50mcg, 250mcg/50mcg and 500mcg/50mcg strengths at a list price of $93.71, $116.44 and $153.14, respectively.

Commenting on the launch, Mylan’s Chief Commercial Officer Tony Mauro said, “We trust that by launching Wixela Inhub at a significantly discounted list price, we will demonstrate the savings that generics can deliver for patients through reduced out-of-pocket costs, as well as the U.S. healthcare system overall.” Mylan will also provide education and training to patients prescribed Wixela Inhub.

Wixela Inhub combines fluticasone propionate, a synthetic corticosteroid, and salmeterol, a long-acting beta2-adrenergic agonist (LABA). The efficacy of Wixela Inhub was found to be equivalent to Advair Diskus in a 28-day, randomized, double-blind, placebo-controlled, parallel group study involving 1128 adult asthma patients.

For more information visit Mylan.com.